WASHINGTON, April 24 (UPI) -- The U.S. Food and Drug Administration has announced a public-private partnership to help identify counterfeit or substandard anti-malarial medicines.
To minimize patient exposure to the public health threat, the FDA has established a partnership with the Skoll Global Threats Fund, the U.S. Pharmacopeia, the National Institutes of Health, the Centers for Disease Control and Prevention, and the multiagency President's Malaria Initiative, led by the U.S. Agency for International Development.